Body mass index does not impact hematopoietic progenitor cell mobilization for autologous hematopoietic cell transplantation

Khouri, Jack; Rybicki, Lisa; Majhail, Navneet S.; Kalaycio, Matt; Pohlman, Brad; Hill, Brian T.; Jagadeesh, Deepa; Dean, Robert M.; Hamilton, Betty K.; Sobecks, Ronald; Koo, Anna P.; Liu, Hien

doi:10.1002/jca.21739

Cited by 6 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several factors such as gender, cholinesterase, platelet count, red cell count, and mean corpuscular volume are associated with HSC mobilization [ 19 , 23 , 37 , 38 ]. Although the correlation between BMI and HSC mobilization has been reported [ 17 , 18 , 19 , 20 , 21 , 22 , 23 , 39 , 40 ], some contradictions arise. For example, some researchers claimed that BMI has no influence on HSC mobilization [ 39 , 40 ], and others reported the opposite results [ 17 , 18 , 19 , 20 , 21 , 22 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

“…Although the correlation between BMI and HSC mobilization has been reported [ 17 , 18 , 19 , 20 , 21 , 22 , 23 , 39 , 40 ], some contradictions arise. For example, some researchers claimed that BMI has no influence on HSC mobilization [ 39 , 40 ], and others reported the opposite results [ 17 , 18 , 19 , 20 , 21 , 22 , 23 ]. This phenomenon indicates that the association between BMI and HSC mobilization remains to be elucidated.…”

Section: Discussionmentioning

confidence: 99%

“…Although the correlation between BMI and HSC mobilization has been reported [17][18][19][20][21][22][23]39,40], some contradictions arise. For example, some researchers claimed that BMI has no influence on HSC mobilization [39,40], and others reported the opposite results [17][18][19][20][21][22][23]. This…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Correlation of Body Mass Index and Proinflammatory Cytokine Levels with Hematopoietic Stem Cell Mobilization

Wang

Liou

Chang

et al. 2022

JCM

View full text Add to dashboard Cite

This study investigated the correlation of body mass index (BMI) and proinflammatory cytokine levels with hematopoietic stem cell (HSC) mobilization triggered by granulocyte colony-stimulating factor (G-CSF). Stem cell donors (n = 309) were recruited between August 2015 and January 2018 and grouped into four groups according to their BMI: underweight (BMI < 18.5 kg/m2, n = 10), normal (18.5 kg/m2 ≦ BMI < 25 kg/m2, n = 156), overweight (25 kg/m2 ≦ BMI < 30 kg/m2, n = 102), and obese (BMI ≧ 30 kg/m2, n = 41). The participants were then administered with five doses of G-CSF and categorized as good mobilizers (CD34 ≧ 180/μL, n = 15, 4.85%) and poor mobilizers (CD34 ≦ 25/μL, n = 14, 4.53%) according to the number of CD34+ cells in their peripheral blood after G-CSF administration. The correlation between BMI and HSC mobilization was then analyzed, and the levels of proinflammatory cytokines in the plasma from good and poor mobilizers were examined by ProcartaPlex Immunoassay. Results showed that BMI was highly correlated with G-CSF-triggered HSC mobilization (R2 = 0.056, p < 0.0001). Compared with poor mobilizers, good mobilizers exhibited higher BMI (p < 0.001) and proinflammatory cytokine [interferon gamma (IFN-γ) (p < 0.05), interleukin-22 (IL-22) (p < 0.05), and tumor necrosis factor alpha (TNF-α) levels (p < 0.05)]. This study indicated that BMI and proinflammatory cytokine levels are positively correlated with G-CSF-triggered HSC mobilization.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Correlation of Body Mass Index and Proinflammatory Cytokine Levels with Hematopoietic Stem Cell Mobilization

Wang

Liou

Chang

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Moreover, different populations exhibit different clinical responses to ABVD-like chemotherapy regimens ( Wen et al, 2022 ). Among them, obese people have implications for chemotherapy administration and dosing ( Khouri et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma

Hu,

Ding,

Zhang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: The role of body mass index (BMI) in the treatment outcomes of lymphoma patients is controversial. While investigating the efficacy of ABVD-like regimen in Hodgkin lymphoma (HL) patients, we observed that obese patients had poor responses. To better understand this clinical phenomenon, we evaluated the effect of BMI on responses to ABVD-like chemotherapy in HL patients.Methods: This retrospective cohort study evaluated the clinical outcomes of all 67 patients with confirmed HL who were treated at the First Affiliated Hospital of Soochow University from November 2016 to March 2023 with an ABVD-like regimen as first-line chemotherapy. Baseline patient characteristics and clinical outcomes were compared across different BMI categories. The primary end-point was the overall response rate defined as the proportion of the HL patients who achieved complete response or partial response. The additional end-points included progression-free survival and overall survival.Results: The median age of the HL patients was 31 years old. Of the patients, 10.4% were obese, and 17.9% patients were overweight. Interim and end-term response evaluations revealed overall response rates of 98.5% and 83.6%, respectively. The proportion of patients with potential poor prognostic factors (IPS risk factors) did not differ significantly in the responders versus non-responders. However, non-responders had a higher average BMI when compared with responders (p = 0.002). Poor overall response rates in higher BMI patients indeed manifested with shorter progression free survival (p = 0.013). The minimum relative dose of the ABVD-like regimen in the overweight and obese groups was significantly lower than in the normal weight group (p < 0.001).Conclusion: Our analyses show that >80% of newly-diagnosed HL patients responded to the ABVD-like regimen. We find that being obese or overweight at the time of diagnosis correlated with a poorer overall response rate and that BMI was an independent risk factor in HL patients treated with the ABVD-like regimen. Lower doses of ABVD-like regimen contributed to the discrepant findings of responses in the high BMI groups. These findings indicate that newly-diagnosed, obese HL patients receiving an ABVD-like regimen require personalized treatment.

show abstract

Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation

et al. 2021

View full text Add to dashboard Cite

Body mass index does not impact hematopoietic progenitor cell mobilization for autologous hematopoietic cell transplantation

Cited by 6 publications

References 27 publications

Correlation of Body Mass Index and Proinflammatory Cytokine Levels with Hematopoietic Stem Cell Mobilization

Correlation of Body Mass Index and Proinflammatory Cytokine Levels with Hematopoietic Stem Cell Mobilization

Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma

Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation

Contact Info

Product

Resources

About